Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
11021
Preliminary efficacy of eye movement desensitization and reprocessing for children aged 1.5–8 years with PTSD: a multiple baseline experimental design (<i>N</i> = 19)
Published 2025“…</p><p>The findings also show a significant reduction in emotional and behavioural problems as well as parenting stress.…”
-
11022
Image 2_Automated radiosynthesis and clinical experience of [18F]SMBT-1 PET imaging for in vivo evaluation of reactive astrocyte in Parkinson's disease: a pilot study.tiff
Published 2025“…[<sup>18</sup>F]SMBT-1 is a promising novel radiotracer for in vivo evaluation of reactive astrogliosis.…”
-
11023
Image 4_Automated radiosynthesis and clinical experience of [18F]SMBT-1 PET imaging for in vivo evaluation of reactive astrocyte in Parkinson's disease: a pilot study.tiff
Published 2025“…[<sup>18</sup>F]SMBT-1 is a promising novel radiotracer for in vivo evaluation of reactive astrogliosis.…”
-
11024
Table 1_Automated radiosynthesis and clinical experience of [18F]SMBT-1 PET imaging for in vivo evaluation of reactive astrocyte in Parkinson's disease: a pilot study.docx
Published 2025“…[<sup>18</sup>F]SMBT-1 is a promising novel radiotracer for in vivo evaluation of reactive astrogliosis.…”
-
11025
Image 3_Automated radiosynthesis and clinical experience of [18F]SMBT-1 PET imaging for in vivo evaluation of reactive astrocyte in Parkinson's disease: a pilot study.tiff
Published 2025“…[<sup>18</sup>F]SMBT-1 is a promising novel radiotracer for in vivo evaluation of reactive astrogliosis.…”
-
11026
Image 1_Automated radiosynthesis and clinical experience of [18F]SMBT-1 PET imaging for in vivo evaluation of reactive astrocyte in Parkinson's disease: a pilot study.tiff
Published 2025“…[<sup>18</sup>F]SMBT-1 is a promising novel radiotracer for in vivo evaluation of reactive astrogliosis.…”
-
11027
DataSheet1_The effect of 12-week high-dose Colostrum Bovinum supplementation on immunological, hematological and biochemical markers in endurance athletes: a randomized crossover p...
Published 2024“…</p>Results<p>At COL<sub>POST</sub> visit the secretory IgA (SIgA) concentration in saliva was significantly higher at POST-EX and REC compared to REST (p<0.05). …”
-
11028
-
11029
Table 3_Genetic association of ACE2 rs2285666 (C>T) and rs2106809 (A>G) and susceptibility to SARS-CoV-2 infection among the Ghanaian population.docx
Published 2025“…Among females, those with the T allele of ACE2 rs2285666 had a 38% decreased susceptibility to SARS-CoV-2 infection under the dominant [adjusted odds ratio (aOR) = 0.62; 95%CI = 0.45–0.85, P = 0.003] and heterozygous advantage models (aOR = 0.62; 95%CI = 0.45–0.86, P = 0.004), after adjusting for confounders, but not thee recessive model (aOR = 0.41; 95%CI = 0.03–5.22, P = 0.490). …”
-
11030
Table 1_Genetic association of ACE2 rs2285666 (C>T) and rs2106809 (A>G) and susceptibility to SARS-CoV-2 infection among the Ghanaian population.docx
Published 2025“…Among females, those with the T allele of ACE2 rs2285666 had a 38% decreased susceptibility to SARS-CoV-2 infection under the dominant [adjusted odds ratio (aOR) = 0.62; 95%CI = 0.45–0.85, P = 0.003] and heterozygous advantage models (aOR = 0.62; 95%CI = 0.45–0.86, P = 0.004), after adjusting for confounders, but not thee recessive model (aOR = 0.41; 95%CI = 0.03–5.22, P = 0.490). …”
-
11031
Table 2_Genetic association of ACE2 rs2285666 (C>T) and rs2106809 (A>G) and susceptibility to SARS-CoV-2 infection among the Ghanaian population.docx
Published 2025“…Among females, those with the T allele of ACE2 rs2285666 had a 38% decreased susceptibility to SARS-CoV-2 infection under the dominant [adjusted odds ratio (aOR) = 0.62; 95%CI = 0.45–0.85, P = 0.003] and heterozygous advantage models (aOR = 0.62; 95%CI = 0.45–0.86, P = 0.004), after adjusting for confounders, but not thee recessive model (aOR = 0.41; 95%CI = 0.03–5.22, P = 0.490). …”
-
11032
DataSheet1_Identifying new biomarkers and potential therapeutic targets for breast cancer through the integration of human plasma proteomics: a Mendelian randomization study and co...
Published 2024“…Therefore, we conducted a comprehensive proteome-wide Mendelian randomization (MR) study to identify novel biomarkers and potential therapeutic targets for breast cancer.…”
-
11033
DataSheet2_Identifying new biomarkers and potential therapeutic targets for breast cancer through the integration of human plasma proteomics: a Mendelian randomization study and co...
Published 2024“…Therefore, we conducted a comprehensive proteome-wide Mendelian randomization (MR) study to identify novel biomarkers and potential therapeutic targets for breast cancer.…”
-
11034
Datasheet1_Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicen...
Published 2024“…The activated partial thromboplastin time in the treatment group decreased significantly (P < 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.…”
-
11035
Datasheet2_Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicen...
Published 2024“…The activated partial thromboplastin time in the treatment group decreased significantly (P < 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.…”
-
11036
Datasheet1_Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicen...
Published 2024“…The activated partial thromboplastin time in the treatment group decreased significantly (P < 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.…”
-
11037
Datasheet2_Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicen...
Published 2024“…The activated partial thromboplastin time in the treatment group decreased significantly (P < 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.…”
-
11038
Table_2_Effect of probiotic supplementation combined with bismuth-containing quadruple therapy on gut microbiota during Helicobacter pylori eradication: a randomized, double-blind,...
Published 2024“…After treatment, the GSRS score decreased significantly in the probiotic group (p = 0.039). …”
-
11039
Image_4_Effect of probiotic supplementation combined with bismuth-containing quadruple therapy on gut microbiota during Helicobacter pylori eradication: a randomized, double-blind,...
Published 2024“…After treatment, the GSRS score decreased significantly in the probiotic group (p = 0.039). …”
-
11040
Image_3_Effect of probiotic supplementation combined with bismuth-containing quadruple therapy on gut microbiota during Helicobacter pylori eradication: a randomized, double-blind,...
Published 2024“…After treatment, the GSRS score decreased significantly in the probiotic group (p = 0.039). …”